CYTEK BIOSCIENCES, INC.
Income Statement
| Line Item | Jul 2026 | Jun 2026 | Apr 2026 | Mar 2026 | Feb 2026 | Dec 2025 | Oct 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $48.1M | — | $44.1M | — | — | — | $52.3M |
| Cost of Revenue | — | $19.8M | — | $22.9M | — | — | — | $24.7M |
| Gross Profit | — | $28.3M | — | $21.3M | — | — | — | $27.6M |
| Gross Margin | — | 58.9% | — | 48.2% | — | — | — | 52.7% |
| Operating Expenses | ||||||||
| Research & Development | — | $9.7M | — | $9.6M | — | — | — | $9.0M |
| SG&A Expense | — | $16.8M | — | $18.5M | — | — | — | $16.1M |
| Operating Income | — | $-11.4M | — | $-18.5M | — | — | — | $-9.2M |
| Operating Margin | — | -23.7% | — | -41.8% | — | — | — | -17.6% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | $-7.8M |
| Income Tax Expense | — | $515.0K | — | $1.5M | — | — | — | $-2.3M |
| Net Income | — | $-12.2M | — | $-18.9M | — | — | — | $-5.5M |
| Net Margin | — | -25.3% | — | -42.7% | — | — | — | -10.5% |
| EPS (Basic) | — | $-0.09 | — | $-0.15 | — | — | — | $-0.04 |
| EPS (Diluted) | — | $-0.09 | — | $-0.15 | — | — | — | $-0.04 |
| Shares Outstanding (Basic) | 130.0M | 129.5M | 129.1M | 128.7M | 128.6M | 128.6M | 127.9M | 127.5M |
| Shares Outstanding (Diluted) | 130.0M | 129.5M | 129.1M | 128.7M | 128.6M | 128.6M | 127.9M | 127.5M |
| Dividends Per Share | — | — | — | — | — | — | — | — |